Imikeraderm

Imiquimod, the active ingredient in Imikeraderm, is a immune response modifier presented as a topical cream for cutaneous use. It is prescribed for certain precancerous skin lesions and viral warts, acting locally to stimulate the skin’s immune defenses. GNH USA supplies Imikeraderm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imikeraderm is a topical immune response modifier indicated for several dermatologic conditions. - Actinic keratosis: clears precancerous lesions by enhancing local immune activity. - Superficial basal cell carcinoma: promotes tumor regression through immune‑mediated mechanisms. - External genital warts: reduces wart burden by stimulating antiviral immune responses.

Local and systemic reactions may occur with topical use of Imiquimod.

Common Side Effects: - Erythema: redness at the application site. - Itching: mild to moderate pruritus. - Burning sensation: transient heat or stinging. - Pain: discomfort during or after application. - Swelling: localized edema. - Crusting: formation of a dry scab.

Serious or Rare Side Effects: - Severe allergic reaction: angioedema or anaphylaxis. - Widespread infection: secondary bacterial infection of treated skin. - Persistent ulceration: non‑healing sores. - Systemic symptoms: fever, malaise, or flu‑like illness. - Lymphadenopathy: swollen regional lymph nodes.

Before using Imikeraderm, consider the following safety measures. - Application area: limit to the prescribed skin region and avoid excessive coverage. - Broken skin: do not apply on open wounds or irritated skin. - Protective gloves: wear gloves during application to reduce accidental exposure. - Monitor reactions: discontinue if severe local inflammation develops. - Immunocompromised patients: use only under specialist guidance. - Store at room temperature: keep in the original container, protect from moisture and light.

Imiquimod may interact with other agents that affect immune function or skin integrity.

Major Interactions (Avoid): - Systemic immunosuppressants: may reduce therapeutic effect. - Live vaccines: concurrent use can compromise vaccine efficacy. - Other topical immune modulators: increased risk of severe skin reactions.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may diminish local immune response. - Antihistamines: may mask early signs of allergic reaction. - Irritating skin products: can exacerbate local irritation.